An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.
The American Society of Clinical Oncology (ASCO) today released an update to its clinical practice guideline for stage IV non-small cell lung cancer. Published in the Journal of Clinical Oncology, the guidance provides recommendations for using systemic therapy—chemotherapy as well as targeted therapy—in first-, second-, and third-line regimens. Following a systematic review of published literature over a 7 year period between January 2007 and February 2014, a panel of experts from ASCO developed the following key recommendations:
Maintenance treatment (treatment after initial response to first-line treatment)
Emphasizing that age alone should not be a factor in the selection of treatment, the guideline recommends early palliative care, along with antitumor treatment.